Paper Details

  1. Home
  2. Paper Details

Combination of cyclic nucleotide modulators with P2Y<sub>12</sub> receptor antagonists as anti-platelet therapy.

Author: ArmstrongPaul C, ChanMelissa V, CrescenteMarilena, FerreiraPlinio M, HobbsAdrian J, KirkbyNicholas S, Lundberg SlingsbyMartina H, ShihChih-Chin, WarnerTimothy D

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Prostacyclin and nitric oxide help maintain platelet quiescence by increasing cyclic nucleotide levels. This study explored the synergistic relationship between cyclic nucleotides and P2Y12 receptor inhibition in platelets. Drugs that modulate cyclic nucleotide tone, like NO-sensitive guanylyl cyclase activators and PDE inhibitors, can be used to inhibit platelets, but the doses needed often cause side effects.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND">Endothelium-derived prostacyclin and nitric oxide elevate platelet cyclic nucleotide levels and maintain quiescence. We previously demonstrated that a synergistic relationship exists between cyclic nucleotides and P2Y<sub>12</sub> receptor inhibition. A number of clinically approv...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/32278335

データ提供：米国国立医学図書館（NLM）

Cyclic Nucleotide Modulators: A New Frontier in Antiplatelet Therapy

The field of [cardiovascular disease] is always seeking new ways to prevent [platelet aggregation] and reduce the risk of [thrombotic events]. This study explores the potential of combining [cyclic nucleotide modulators] with [P2Y12 receptor antagonists] as a novel antiplatelet therapy. The authors delve into the synergistic relationship between [cyclic nucleotides] and [P2Y12 receptor inhibition], highlighting the potential for a more effective antiplatelet strategy.

Synergy in Antiplatelet Therapy: A Powerful Combination

This study provides compelling evidence for the potential benefits of combining [cyclic nucleotide modulators] with [P2Y12 receptor antagonists]. The synergistic interaction between these two classes of drugs could lead to a more potent antiplatelet effect, potentially reducing the risk of [thrombotic events]. However, further research is needed to optimize this approach and address potential side effects.

Protecting Your Heart: A Multifaceted Approach

Maintaining cardiovascular health is crucial for overall well-being. This study underscores the importance of a multifaceted approach to [cardiovascular disease] prevention, involving lifestyle modifications, such as [diet and exercise], as well as appropriate medical treatment. Working closely with your healthcare provider to develop a personalized plan that addresses your individual needs and risk factors is essential for achieving optimal cardiovascular health.

Dr. Camel's Conclusion

This study is like a desert caravan, bringing together the best of both worlds in antiplatelet therapy. The synergistic potential of [cyclic nucleotide modulators] and [P2Y12 receptor antagonists] holds promise for a more effective strategy to combat [cardiovascular disease]. However, like a camel navigating a winding desert path, we must continue to explore and research this approach to ensure its safety and efficacy for the long-term.

Date :
  1. Date Completed 2021-05-14
  2. Date Revised 2023-08-29
Further Info :

Pubmed ID

32278335

DOI: Digital Object Identifier

S1538-7836(22)01333-2

Related Literature

Article Analysis
・Side Effects of dipyridamole
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.